Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy

@inproceedings{Richardson2009LenalidomideIM,
  title={Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy},
  author={Paul G Richardson and Constantine S. Mitsiades and Jacob P Laubach and Robert L. Schlossman and Irene M Ghobrial and Teru Hideshima and Nikhil C. Munshi and Kenneth C. Anderson},
  booktitle={Core evidence},
  year={2009}
}
INTRODUCTION Multiple myeloma (MM) is a relatively common and incurable hematological malignancy. Currently, there is no single standard therapy, with choice of treatment dependent on individual patient factors. Lenalidomide is an immunomodulatory drug with potent antitumor, antiangiogenic, immunomodulatory, and proapoptotic activity in MM. AIMS To evaluate the evidence for the use of lenalidomide in its current indication in relapsed or refractory MM, and additionally its investigational use… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-8 OF 8 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 139 REFERENCES

Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2007
VIEW 15 EXCERPTS
HIGHLY INFLUENTIAL

Results of a phase I/II trial of Deutsche Studiengruppe Multiples Myelom, showing efficacy and safety of RAD regimen (Revlimid, Adriamycin, dexamethasone) in relapsed/refractory multiple myeloma

S Knop, C Gerecke, P Liebisch
  • [abstract]. Haematologica
  • 2008
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Lenalidomide--the phoenix rises.

  • The New England journal of medicine
  • 2007
VIEW 13 EXCERPTS
HIGHLY INFLUENTIAL